Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

IOM Reverses Finding of Childhood AML Link to Parent’s Vietnam Service

April 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 4
Volume 11
Issue 4

WASHINGTON-After further review, a committee of the Institute of Medicine (IOM) has rescinded its earlier finding of a suggestive link between the exposure of veterans to herbicides used during the Vietnam War and an increased risk of their offspring developing acute myelogenous leukemia (AML). The committee’s reanalysis followed the finding that one study that it had relied on was in error.

WASHINGTON—After further review, a committee of the Institute of Medicine (IOM) has rescinded its earlier finding of a suggestive link between the exposure of veterans to herbicides used during the Vietnam War and an increased risk of their offspring developing acute myelogenous leukemia (AML). The committee’s reanalysis followed the finding that one study that it had relied on was in error.

The panel based its prior conclusion, contained in a report released in April 2001, in part on an Australian study that found a statistical link between the service of Australian veterans in Vietnam and the incidence of AML among their children. That study, however, was later found to contain a miscalculation that resulted in the conclusion that the children had a significantly increased risk of the disease. The actual incidence was within the range that would be expected in the general population.

The IOM panel also included two new studies, one from Germany and the other from Norway, in its newest review of data. The two studies examined the incidence of AML in the children of parents who had experienced occupational exposure to pesticides and found no significant difference, compared with children of unexposed parents.

Articles in this issue

Infection Rate Low With Peripheral and Nontunneled CVCs Nontunneled Catheters
Virtual Shared Specimen Resource ‘Essential’
DHA Conjugate Increases Paclitaxel Uptake by Tumor Cells
Letrozole Superior to Tamoxifen in Metastatic Breast Cancer
S-8184 Paclitaxel Emulsion Promising in Phase I Study
HIV+ Veterans Have Higher Rates of Unusual Cancers
A Clinician’s Perspective on ASCO 2001: Going After the Epidermal Growth Factor Receptor
Online Breast Cancer Support Groups Beneficial
Survival Benefit With Capecitabine/Docetaxel
FDA Approves Zometa for Cancer-Related Bone Complications
New Blood Test for Early Ovarian Cancer in Clinical Trials
Race Per Se Does Not Predict Extracapsular Prostate Cancer
HIV-Related Lymphoma Differs in Those With Early vs Advanced HIV Infection
Equal Access Erases Racial Disparity in Prostate Cancer Stage
FDA Approves Zevalin for Use With Rituxan in Refractory NHL Patients
Recent Videos
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Related Content
Advertisement

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS in relapsed/refractory LBCL.

Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL

Roman Fabbricatore
November 3rd 2025
Article

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS in relapsed/refractory LBCL.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

American Society for Transplantation and Cellular Therapy
October 31st 2025
Article

Researchers have determined that matched allogeneic donor CD19 CAR T-cell therapy, delivered as a CAR-modified donor lymphocyte infusion, is safe and clinically active for adults with relapsed B-ALL following allogeneic transplant.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


What Path to Approval Has Dasatinib Taken in CML/ALL?

What Path to Approval Has Dasatinib Taken in CML/ALL?

Ariana Pelosci
October 27th 2025
Article

Over the past 4 years, the FDA has accepted a number of NDA submissions for dasatinib, but it has yet to receive approval in CML/ALL.


PET-adapted strategies enhance treatment for advanced classical Hodgkin lymphoma, optimizing outcomes through individualized escalation and de-escalation based on PET results.

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era

Wael Abdulla Moh Khair, MD
October 26th 2025
Article

Related Content
Advertisement

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS in relapsed/refractory LBCL.

Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL

Roman Fabbricatore
November 3rd 2025
Article

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS in relapsed/refractory LBCL.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

American Society for Transplantation and Cellular Therapy
October 31st 2025
Article

Researchers have determined that matched allogeneic donor CD19 CAR T-cell therapy, delivered as a CAR-modified donor lymphocyte infusion, is safe and clinically active for adults with relapsed B-ALL following allogeneic transplant.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


What Path to Approval Has Dasatinib Taken in CML/ALL?

What Path to Approval Has Dasatinib Taken in CML/ALL?

Ariana Pelosci
October 27th 2025
Article

Over the past 4 years, the FDA has accepted a number of NDA submissions for dasatinib, but it has yet to receive approval in CML/ALL.


PET-adapted strategies enhance treatment for advanced classical Hodgkin lymphoma, optimizing outcomes through individualized escalation and de-escalation based on PET results.

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era

Wael Abdulla Moh Khair, MD
October 26th 2025
Article

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.